PTCT Ptc Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PTCT

Price (delayed)

$63.49

Market cap

$5.3B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.46

Enterprise value

$5.43B

?
Relative Growth: Rel. Growth: 16
Relative Strength: Rel. Strength: 37
Relative Valuation: Rel. Valuation: 13
Relative Profitability: Rel. Profitability: 42

PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust ...

Highlights
The company's debt has surged by 55% YoY but it fell by 9% QoQ
The quick ratio rose by 40% year-on-year but it has declined by 4.7% since the previous quarter
The net income has plunged by 176% from the previous quarter and by 114% YoY
The EPS has dropped by 128% since the previous quarter and by 115% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ptcbio.com
Peers: FATE VRTX SRPT XNCR

Key stats

What are the main financial stats of PTCT

PTCT stock price

How has the Ptc Therapeutics stock price performed over time
Intraday
0.21%
1 week
-2.98%
1 month
5.96%
1 year
-15.29%
YTD
-16.42%
QTD
-1.99%

Financial performance

How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$1.16B
Gross profit
$1.08B
Operating income
$147.7M
Net income
-$105.97M
Gross margin
93.2%
Net margin
-9.2%
The net income has plunged by 176% from the previous quarter and by 114% YoY
The company's net margin has shrunk by 142% QoQ and by 122% YoY
The company's operating income has shrunk by 81% YoY but it rose by 18% QoQ
PTCT's operating margin has dropped by 70% year-on-year but it is up by 2.4% since the previous quarter

Price vs fundamentals

How does PTCT's price correlate with its fundamentals

Growth

What is Ptc Therapeutics's growth rate over time

Valuation

What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
4.59
EV/EBIT
47.86
EV/EBITDA
29.9
EV/Sales
4.7
The EPS has dropped by 128% since the previous quarter and by 115% year-on-year
Ptc Therapeutics's equity has decreased by 23% YoY and by 16% QoQ
Ptc Therapeutics's revenue has decreased by 35% YoY but it has increased by 15% from the previous quarter
The price to sales (P/S) is 18% higher than the 5-year quarterly average of 3.9 but 15% lower than the last 4 quarters average of 5.4

Efficiency

How efficient is Ptc Therapeutics business performance
Ptc Therapeutics's ROA has plunged by 169% from the previous quarter and by 111% YoY
The ROIC has plunged by 92% YoY and by 21% from the previous quarter
The ROS has dropped by 80% year-on-year and by 16% since the previous quarter

Dividends

What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTCT.

Financial health

How did Ptc Therapeutics financials performed over time
The total assets is 6% less than the total liabilities
Ptc Therapeutics's current ratio has increased by 41% YoY but it has decreased by 3.5% QoQ
The quick ratio rose by 40% year-on-year but it has declined by 4.7% since the previous quarter
The company's debt has surged by 55% YoY but it fell by 9% QoQ
PTCT's debt to equity is down by 27% year-on-year but it is up by 21% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.